Media

Oncopeptides – Invitation to presentation of the year-end report 2025

Intervacc announces change of CEO

Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Doctrin appoints Unn Hellberg as new CEO

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Kivu Bioscience Appoints Julie Hambleton, M.D., to its Board of Directors